Look­ing to move past an R&D fi­as­co, Ipsen poach­es their new CEO from Sanofi

Ipsen has turned to an­oth­er Paris-based bio­phar­ma com­pa­ny for its next CEO.

Sanofi Pas­teur chief David Loew — who’s been lead­ing one of the most ad­vanced ef­forts to de­vel­op vac­cines for Covid-19 — is mak­ing the jour­ney to Ipsen, 5 months af­ter David Meek jumped ship to run a start­up in late-stage de­vel­op­ment.

Loew ar­rives as Ipsen works to get back on track with their rare bone dis­ease drug palo­varotene, picked up in the $1.3 bil­lion Clemen­tia buy­out, which was slammed with a par­tial hold af­ter re­searchers ob­served cas­es of “ear­ly growth plate clo­sure” in pa­tients un­der the age of 14. But they are push­ing ahead with the over-14 crowd af­ter writ­ing down slight­ly more than half of its ini­tial de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.